HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Anxiety disorder caused by ketamine — Clinical Guidelines

Overview

Anxiety disorder caused by ketamine refers to the emergence of significant anxiety symptoms in patients following ketamine administration, often observed in the context of its use for chronic pain management, psychiatric disorders, or procedural sedation. Ketamine, while effective for short-term pain relief and as a rapid-acting antidepressant, can induce psychomimetic side effects, including anxiety, which can complicate treatment and patient outcomes. This condition is particularly relevant in clinical settings where ketamine is increasingly utilized off-label due to its unique pharmacological properties. Understanding and managing ketamine-induced anxiety is crucial for ensuring patient safety and optimizing therapeutic outcomes in day-to-day practice. 1 2 5

Pathophysiology

Ketamine's mechanism of inducing anxiety likely stems from its actions on the N-methyl-D-aspartate (NMDA) receptors and other neurotransmitter systems. As an NMDA receptor antagonist, ketamine disrupts normal glutamatergic signaling, which plays a critical role in mood regulation and anxiety processing. This disruption can lead to altered activity in brain regions such as the amygdala and prefrontal cortex, areas heavily involved in fear and anxiety responses. Additionally, ketamine's effects on other receptors, including serotonin and norepinephrine systems, contribute to its psychomimetic properties, including anxiety. The dissociative state induced by ketamine can exacerbate feelings of detachment and unease, further precipitating anxiety symptoms. 2 4 9

Epidemiology

The precise incidence and prevalence of ketamine-induced anxiety are not well-documented in large-scale epidemiological studies, partly due to its off-label use and varied clinical applications. However, anecdotal evidence and case reports suggest that anxiety symptoms are more commonly reported in patients receiving higher doses or prolonged exposure to ketamine, particularly in settings such as chronic pain management and psychiatric treatment. Age and pre-existing psychiatric conditions may increase susceptibility, though specific demographic trends remain speculative without robust longitudinal data. 1 5

Clinical Presentation

Ketamine-induced anxiety typically manifests as heightened anxiety, restlessness, and in some cases, panic attacks. Patients may exhibit symptoms such as palpitations, sweating, tremors, and heightened vigilance. Atypical presentations can include dissociative symptoms like derealization or depersonalization, which can complicate the clinical picture. Red-flag features include severe agitation, suicidal ideation, or significant functional impairment, necessitating prompt clinical evaluation and intervention. 1 2 9

Diagnosis

Diagnosing ketamine-induced anxiety involves a thorough clinical assessment, including a detailed history of ketamine exposure and symptom onset. Specific criteria for diagnosis include:

History of Ketamine Use: Recent or ongoing administration of ketamine, particularly at higher doses or via routes that enhance psychomimetic effects (e.g., intravenous).

Symptom Onset Timing: Anxiety symptoms developing shortly after ketamine administration.

Exclusion of Other Causes: Ruling out other potential triggers or underlying psychiatric conditions through clinical evaluation and possibly psychological assessments.

Required Tests: No specific laboratory tests are definitive, but monitoring vital signs and assessing cognitive function can provide supportive evidence.

Differential Diagnosis:

- Generalized Anxiety Disorder: Typically lacks temporal association with ketamine use. - Panic Disorder: Often characterized by spontaneous panic attacks without clear triggers related to medication. - Substance-Induced Anxiety Disorder: Requires distinguishing based on the temporal relationship and specific substance effects. 1 2 5

Management

First-Line Management

Dose Adjustment: Reduce ketamine dose or frequency if feasible.

Alternative Analgesics: Consider switching to non-ketamine alternatives for pain management, such as gabapentinoids or other NMDA receptor modulators with fewer psychomimetic effects.

Psychological Support: Provide supportive psychotherapy or cognitive-behavioral therapy (CBT) to address anxiety symptoms.

Second-Line Management

Anxiolytics: Short-term use of benzodiazepines or other anxiolytics to manage acute anxiety episodes.

Adjunctive Medications: Addition of selective serotonin reuptake inhibitors (SSRIs) or other antidepressants to stabilize mood and reduce anxiety.

Refractory Cases / Specialist Escalation

Consultation with Psychiatrist: For comprehensive psychiatric evaluation and management.

Multidisciplinary Approach: Involvement of pain management specialists, anesthesiologists, and mental health professionals to tailor a holistic treatment plan.

Monitoring and Support: Regular follow-ups to monitor both physical and psychological symptoms, adjusting treatment as necessary. 1 2 5 9

Complications

Acute Complications: Severe agitation, hallucinations, and suicidal ideation may require immediate intervention.

Long-Term Complications: Chronic anxiety, cognitive impairment, and potential development of substance use disorders if ketamine use continues.

Management Triggers: Persistent or worsening anxiety symptoms necessitate reassessment of ketamine therapy and potential discontinuation. Referral to a specialist is warranted if complications arise. 1 2 5 9

Prognosis & Follow-Up

The prognosis for patients experiencing ketamine-induced anxiety varies based on the severity and duration of symptoms, as well as the effectiveness of intervention. Early recognition and management generally yield better outcomes. Key prognostic indicators include:

Response to Treatment: Rapid improvement with dose adjustment or alternative therapies.

Patient Engagement: Active participation in psychological support and adherence to prescribed treatments.

Recommended follow-up intervals typically include:

Initial Follow-Up: Within 1-2 weeks post-intervention to assess symptom resolution.

Subsequent Monitoring: Monthly evaluations for the first 3 months, then every 3-6 months depending on symptom stability. 1 5

Special Populations

Pediatrics

Ketamine use in pediatric patients requires heightened vigilance due to their heightened sensitivity to psychomimetic effects. Close monitoring for anxiety and other adverse reactions is essential, with careful dose titration and psychological support.

Elderly

Elderly patients may be more susceptible to cognitive side effects and anxiety due to age-related changes in brain function. Tailored dosing and frequent reassessment are critical.

Comorbid Psychiatric Conditions

Patients with pre-existing anxiety disorders or other psychiatric comorbidities may require more cautious ketamine use and closer monitoring for exacerbation of symptoms. 1 2 5

Key Recommendations

Supervised Ketamine Administration: Ensure ketamine is administered under strict supervision by trained specialists to monitor for and manage psychomimetic side effects, including anxiety (Evidence: Strong 1).

Patient Selection Criteria: Carefully select patients for ketamine therapy, considering their psychiatric history and risk factors for anxiety (Evidence: Moderate 2).

Dose Optimization: Tailor ketamine dosing to minimize psychomimetic effects while maintaining therapeutic efficacy (Evidence: Moderate 1).

Psychological Support Integration: Incorporate psychological support, such as CBT, alongside pharmacological interventions (Evidence: Moderate 5).

Regular Monitoring: Implement regular follow-up assessments to detect early signs of anxiety and other adverse effects (Evidence: Moderate 1).

Alternative Therapies Consideration: Explore and consider alternative pain management or psychiatric treatments when ketamine-induced anxiety is significant (Evidence: Moderate 2).

Referral for Refractory Cases: Escalate management to psychiatric specialists for patients with persistent anxiety symptoms (Evidence: Expert opinion 5).

Documentation of Symptoms: Maintain detailed records of ketamine exposure and symptom onset to aid in diagnosis and management (Evidence: Expert opinion 1).

Avoid Unsupervised Use: Prohibit unsupervised or off-label use of ketamine to mitigate risks of adverse psychological effects (Evidence: Expert opinion 2).

Education for Healthcare Providers: Ensure healthcare providers are educated on recognizing and managing ketamine-induced anxiety (Evidence: Expert opinion 5).

References

1 Pickering G, Morel V, Voute M. Managing Chronic Pain: The Ketamine Option. CNS drugs 2026. link 2 Ferraro MC, Cashin AG, Visser EJ, Abdel Shaheed C, Wewege MA, Wand BM et al.. Ketamine and other NMDA receptor antagonists for chronic pain. The Cochrane database of systematic reviews 2025. link 3 Lang B, Wang H, Fu Y, Zeng L, Huang L, Zhang Q et al.. Efficacy and safety of intranasal midazolam versus intranasal ketamine as sedative premedication in pediatric patients: a meta-analysis of randomized controlled trials. BMC anesthesiology 2022. link 4 Vogt KM, Ibinson JW, Smith CT, Citro AT, Norton CM, Karim HT et al.. Midazolam and Ketamine Produce Distinct Neural Changes in Memory, Pain, and Fear Networks during Pain. Anesthesiology 2021. link 5 Harvey M, Sleigh J, Voss L, Bickerdike M, Dimitrov I, Denny W. KEA-1010, a ketamine ester analogue, retains analgesic and sedative potency but is devoid of Psychomimetic effects. BMC pharmacology & toxicology 2019. link 6 Liebe T, Li S, Lord A, Colic L, Krause AL, Batra A et al.. Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. The international journal of neuropsychopharmacology 2017. link 7 Pan X, Zeng X, Hong J, Yuan C, Cui L, Ma J et al.. Effects of Ketamine on Metabolomics of Serum and Urine in Cynomolgus Macaques (Macaca fascicularis). Journal of the American Association for Laboratory Animal Science : JAALAS 2016. link 8 Klinger F, Bajric M, Salzer I, Dorostkar MM, Khan D, Pollak DD et al.. δ Subunit-containing GABAA receptors are preferred targets for the centrally acting analgesic flupirtine. British journal of pharmacology 2015. link 9 Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA et al.. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. Journal of psychiatric research 2014. link 10 Richter N, Schmidt S, Pigatto GR, Francis RCE, Schüttler J, Cunha TM et al.. Dissociating pain dimensions in cold allodynia: subanesthetic ketamine reveals heritable affective-motivational traits in mice. Pain 2026. link 11 Alijanpour S, Golshani SP, Ebrahimi-Ghiri M, Zarrindast MR, Khakpai F. Ketamine and crocin exposure modulate anxiety, depression, memory, and pain processes in adolescent female Wistar rats. Behavioural pharmacology 2025. link 12 Xu R, Zhu W, Xu X, Yao Y, Liu Q, Yang Y et al.. S-Ketamine Alleviates Anxiety-Induced Chronic Postoperative Pain by Affecting Glucose Metabolism of Striatal Microglia in a Rat Model. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2025. link 13 Mirfazaelian H, Darafshi AS, Sedaghat M, Akbari H. The Effectiveness of Intranasal Ketamine on Intramuscular Ketamine Injection Pain Among Children in the Emergency Department, a Randomized, Controlled Trial. Pediatric emergency care 2025. link 14 Zaki C. Beyond Anesthesia: Ketamine's Expanding Role in Chronic Pain and Psychiatric Disorders. Journal of integrative neuroscience 2025. link 15 Colón C, Early P, Muñana K, Olby N, Mariani C, Mancini S et al.. Pharmacokinetics of subcutaneous ketamine administration via the Omnipod® system in dogs. Journal of veterinary pharmacology and therapeutics 2024. link 16 Zhang A, Zhou Y, Zheng X, Zhou W, Gu Y, Jiang Z et al.. Effects of S-ketamine added to patient-controlled analgesia on early postoperative pain and recovery in patients undergoing thoracoscopic lung surgery: A randomized double-blinded controlled trial. Journal of clinical anesthesia 2024. link 17 Davis A, Fassassi C, Dove D, Drapkin J, Likourezos A, Gohel A et al.. Analgesic Efficacy of Oral Aspirin/Ketamine Combination for Management of Acute Musculoskeletal Pain in the Emergency Department - A Proof of Concept Pilot Study. The Journal of emergency medicine 2022. link 18 Olofsen E, Kamp J, Henthorn TK, van Velzen M, Niesters M, Sarton E et al.. Ketamine Psychedelic and Antinociceptive Effects Are Connected. Anesthesiology 2022. link 19 Salort G, Álvaro-Bartolomé M, García-Sevilla JA. Ketamine-induced hypnosis and neuroplasticity in mice is associated with disrupted p-MEK/p-ERK sequential activation and sustained upregulation of survival p-FADD in brain cortex: Involvement of GABA. Progress in neuro-psychopharmacology & biological psychiatry 2019. link 20 Chen YW, Sherpa AD, Aoki C. Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior. The International journal of eating disorders 2018. link 21 Aminiahidashti H, Shafiee S, Hosseininejad SM, Firouzian A, Barzegarnejad A, Kiasari AZ et al.. Propofol-fentanyl versus propofol-ketamine for procedural sedation and analgesia in patients with trauma. The American journal of emergency medicine 2018. link 22 Radford KD, Park TY, Lee BH, Moran S, Osborne LA, Choi KH. Dose-response characteristics of intravenous ketamine on dissociative stereotypy, locomotion, sensorimotor gating, and nociception in male Sprague-Dawley rats. Pharmacology, biochemistry, and behavior 2017. link 23 Fiorelli A, Mazzella A, Passavanti B, Sansone P, Chiodini P, Iannotti M et al.. Is pre-emptive administration of ketamine a significant adjunction to intravenous morphine analgesia for controlling postoperative pain? A randomized, double-blind, placebo-controlled clinical trial. Interactive cardiovascular and thoracic surgery 2015. link 24 Monsereenusorn C, Rujkijyanont P, Traivaree C. The clinical effect of fentanyl in comparison with ketamine in analgesic effect for oncology procedures in children: a randomized, double-blinded, crossover trial. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2015. link 25 Rasmussen KG. Psychiatric side effects of ketamine in hospitalized medical patients administered subanesthetic doses for pain control. Acta neuropsychiatrica 2014. link 26 O'Malley PA. Ketamine-a returning option for procedural sedation and analgesia in adults. Clinical nurse specialist CNS 2014. link 27 Ling Y, Yang Y, Bian S, Tu Y. Study on the mechanism of potential response of a ketamine-sensitive membrane electrode. Drug testing and analysis 2010. link 28 Zanette G, Micaglio M, Zanette L, Manani G, Facco E. Comparison between ketamine and fentanyl-droperidol for rectal premedication in children: a randomized placebo controlled trial. Journal of anesthesia 2010. link 29 Sprenger T, Valet M, Woltmann R, Zimmer C, Freynhagen R, Kochs EF et al.. Imaging pain modulation by subanesthetic S-(+)-ketamine. Anesthesia and analgesia 2006. link 30 Golparvar M, Saghaei M, Sajedi P, Razavi SS. Paradoxical reaction following intravenous midazolam premedication in pediatric patients - a randomized placebo controlled trial of ketamine for rapid tranquilization. Paediatric anaesthesia 2004. link 31 Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. Journal of pain and symptom management 1999. link00011-1) 32 Hara K, Yanagihara N, Minami K, Ueno S, Toyohira Y, Sata T et al.. Ketamine interacts with the noradrenaline transporter at a site partly overlapping the desipramine binding site. Naunyn-Schmiedeberg's archives of pharmacology 1998. link 33 Andersen S, Dickenson AH, Kohn M, Reeve A, Rahman W, Ebert B. The opioid ketobemidone has a NMDA blocking effect. Pain 1996. link03123-5)

Anxiety disorder caused by ketamine